Security key
62818Q302
MUSTANG BIO, INC. - Common Stock, $0.0001 Par Value (MBIO)
CUSIP: 62818Q302
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, $0.0001 Par Value
- Total 13F shares
- 113,859
- Total 13F value
- $142,327
- Share change
- +113,737
- SEC-reported price per share
- $1.25
- Number of holders
- 15
- Value change
- +$142,173
- Number of buys
- 13
- Shares outstanding
- 6,715,538
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
15
Top holders
10
MBIO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
MUSTANG BIO, INC. SEC filings
MUSTANG BIO, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 62818Q302
Recent filing periods:
Ownership snapshot
Top reported holders of MBIO - MUSTANG BIO, INC. - Common Stock, $0.0001 Par Value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Fortress Biotech, Inc.
Disclosed value leader
Fortress Biotech, Inc.
Comparable rows
2/15
Latest evidence
31 Dec 2024
13D/G
13F
3/4/5
Lead comparable stake: 12%
13 rows are not safely comparable across share classes.
13D/G row: Fortress Biotech, Inc.
Showing 1-6 of 15 holder rows.
Quick read
Fortress Biotech, Inc. leads the comparable SEC ownership view at 12%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Fortress Biotech, Inc.'s linked filing trail.
Comparable ownership
Top 2
Fortress Biotech, Inc.
12%
ARMISTICE CAPITAL, LLC
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. |
13D/G
|
12%
Reported 13D/G
· 31 Dec 2024
|
$1,708,057
6,569,450 shares
|
$0 | 31 Dec 2024 |
| ARMISTICE CAPITAL, LLC |
13F
13D/G
Company
|
5%
Reported 13D/G
· 31 Mar 2025
|
$638,358
3,606,543 shares
|
— | 31 Dec 2024 |
| Brian Achenbach |
3/4/5
SVP, Fin. & Corp. Controller
|
—
denominator unverified
|
$74,738
144,729 shares
|
— | 08 Dec 2021 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
denominator unverified
|
$50,347
284,437 shares
|
— | 31 Dec 2024 |
| Lindsay A. Rosenwald MD |
3/4/5
Director
|
—
denominator unverified
|
$31,255
60,525 shares
|
— | 05 Jul 2023 |
| Michael S. Weiss |
3/4/5
Director
|
—
denominator unverified
|
$25,633
49,637 shares
|
— | 05 Jul 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
15
Shares
113,859
Rows available
15
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q2 2026 Across Filers
Q2 2026 holders
23
Q1 2025 holders
15
Holder diff
-8
| Investor | Q2 2026 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q2 2026 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend